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Abstract
Background
Every year more than 800 patients in Denmark are diagnosed with renal cell carcinoma
(RCC) of which 3–5% are expected to be part of a hereditary renal cancer syndrome. We
performed genetic screening of causative and putative RCC-genes (VHL, FH, FLCN, MET,
SDHB, BAP1, MITF, CDKN2B) in RCC-patients suspected of a genetic predisposition.
Methods
The cohort consisted of forty-eight Danish families or individuals with early onset RCC, a
family history of RCC, a family history of RCC and melanoma or both RCC- and melanoma
diagnosis in the same individual. DNA was extracted from peripheral blood samples or can-
cer-free formalin-fixed paraffin-embedded tissue.
Results
One start codon variant of unknown clinical significance (VUS) (c.3G>A, p.Met1Ile) and one
missense VUS (c.631A>C, p.Met211Leu) was found in VHL in a patient with RCC-onset at
twenty-eight years of age but without other manifestations or family history of von Hippel-
Lindau (VHL). Furthermore, in three families we found three different variants in BAP1, one
of which was a novel non-segregating missense variant (c.1502G>A, p.Ser501Asn) in a
family with two brothers affected with RCC. Finally, we found the known E318K-substitution
in MITF in a RCC-affected member of a family with multiple melanomas. No variants were
detected in CDKN2B.
Conclusion
Although we did find three VUS’s in BAP1 in three families and a pathogenic variant in MITF
in one family, pathogenic germline variants in BAP1, MITF or CDKN2B are not frequent
causes of hereditary renal cancer in Denmark. It is possible that the high prevalence of risk
factors such as male gender, smoking and obesity has influenced the development of
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cancer in the patients of the current study. Further investigations into putative predisposing
genes and risk factors of RCC are necessary to enable better prediction of renal cancer risk
or presymptomatic testing of relatives in hereditary renal cancer families.
Introduction
Renal cell carcinomas (RCCs) are the most frequent malignancies of the kidneys and comprise
different subtypes with highly heterogeneous histopathology: 70–75% are clear cell (ccRCC),
10–16% are papillary (type 1 or 2), 5% are chromophobe, and the remaining 10% consists of
other subtypes such as collecting duct and medullary tumors [1]. In Denmark, RCC represents
2–3% of all cancers with an average incidence of 825 cases/year for 2011–2015[2]. Cancer
detection at an early stage with identification of small and localized tumors decreases morbid-
ity and thus presymptomatic screening and surveillance of patients with high risk of RCC
development is likely to decrease RCC mortality [3,4].
Twice as many men as women are diagnosed with RCC and a documented association
between RCC and smoking, high blood pressure and obesity has been found. Several other
risk factors for RCC such as environmental exposure to trichloroethylene (TCE) and cad-
mium, multiparity in women and pre-existing renal disease, e.g. acquired renal cysts, long
term dialysis and kidney transplantation have been proposed, but the association has not been
documented to the same degree [5].
Most cases of RCC are sporadic but occasionally familial clustering occurs. Early age of
onset, multiple and/or bilateral lesions and several malignant and benign masses in the kidneys
characterize RCC patients with a genetic predisposition [6]. Approximately 3–5% of RCCs are
estimated to be part of a hereditary cancer syndrome of which most are inherited in an autoso-
mal dominant fashion [7].
The majority of hereditary RCCs are caused by pathogenic germline variants in the VHL
gene (OMIM #608537) that causes von Hippel-Lindau syndrome (VHL), while other predis-
posing syndromes include hereditary leiomyomatosis and RCC (FH, OMIM#136850), Birt-
Hogg-Dubé (FLCN, OMIM #607273), hereditary papillary RCC (MET, OMIM#164860),
hereditary paraganglioma and RCC (SDHB, OMIM#185470) and constitutional chromosome
3 translocations of t(3;8)(p14.2;q24.1) (reviewed in [8], OMIM#14470). However, for several
multi-case or early onset RCC families, screening for known pathogenic variants in the most
frequent causative genes VHL, FH, FLCN, and MET yields no eligible explanation for the accu-
mulation of RCC in the family, suggesting that unknown genes predisposing for RCC most
likely exist.
One putative RCC-susceptibility gene is BAP1(OMIM#603089); a deubiquitinase associated
with multiprotein complexes regulating pathways in the cell cycle, cellular differentiation and
the DNA damage response [9]. BAP1 is localized on the short arm of chromosome 3. A broad
tumor spectrum accompanies BAP1 pathogenic germline variants [10,11] and although this
spectrum has not yet been fully elucidated, pathogenic variants in BAP1 is known to predis-
pose to cutaneous and uveal melanoma and mesothelioma and is suspected of playing a role in
the development of other cancers such as breast cancer, cholangiocarcinoma [12], cancer of
the pancreas [10] and basal cell carcinoma [13,14]. Furthermore BAP1 has been found to be
mutated in tissue from sporadic malignant renal tumors, which are associated with a high
tumor grade and bad prognosis [15,16]. Pathogenic germline variants have been found to
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segregate with the disease in high risk RCC families in France and the US [17,18], indicating
that RCC might be an integral part of the BAP1 tumor spectrum.
This hypothesis has recently been supported by Haugh et al who by review of the literature
reported twenty cases of RCC in 215 patients with pathogenic BAP1-variants corresponding to
an estimated penetrance for RCC of 9% [19].Microphthalmia-associated transcription factor
(MITF) regulates the expression of genes involved in the cell cycle, cellular proliferation and
differentiation [20]. In 2011 Bertolotto et al discovered a germline amino acid substitution
(E318K) in MITF (OMIM#156845) that occurred with a significantly higher frequency in
patients with melanoma, RCC or both cancers when compared to controls [21]. The E318K
variant has been found to increase growth, proliferation and migration of melanocytes and
renal cells, and although the full picture of MITFs contribution to oncogenesis is yet unknown,
the variant is thought to enable MITF to act as an oncogene and thereby predispose to mela-
noma and RCC [22].
CDKN2B (OMIM#600431) is located close to the tumor suppressor gene CDKN2A in
region 9p21.3 on the short arm of chromosome 9; a region that often contains genetic alter-
ations and is involved in the development of several types of tumors. CDKN2B controls cellu-
lar growth by forming complexes with CDK4 and CDK6, thus inhibiting progression into the
G1 phase of the cell cycle [23]. CDKN2B has previously been linked to a wide variety of dis-
eases including type-2 diabetes mellitus, atherosclerosis, primary open-angle glaucoma and
leukemia. In 2015, Jafri et al discovered a novel nonsense variant in CDKN2B in a high risk
RCC family. DNA was available from five family members of whom the variant was found in
two affected brothers and not in three of their cancer free siblings. Furthermore, two novel
missense variants in CDKN2B were found in a cohort of fifty individuals with features of non-
syndromic hereditary RCC [24].
In this study we have examined whether pathogenic variants in BAP1, MITF or CDKN2B
play a role in the development of RCC. In Denmark, patients with early onset RCC and fami-
lies with accumulation of RCCs are usually screened for variants in four genes: VHL, FH,
FLCN and MET. At Copenhagen University Hospital SDHB-screening is also performed, since
pathogenic variants in SDHB are correlated with an increased risk of paraganglioma, pheo-
chromocytoma and RCC and standard chromosome analysis is performed to examine for the
known chromosome translocation t(3;8)(p14.2;q24.1). We have performed analyses of the
aforementioned RCC causative genes and screened for variants in the putative RCC genes
BAP1, MITF and CDKN2B. Chromosome analysis has not been performed in the current
study. We have analyzed DNA extracted from peripheral blood samples in forty-four families
and DNA extracted from fresh-frozen paraffin embedded tissue in four families to further elu-
cidate the genetic etiology of RCC and hopefully enable presymptomatic genetic testing to rel-
atives in these families.
Methods
Study population
The study is conducted at the Department of Clinical Genetics, Copenhagen University Hospi-
tal, Copenhagen, Denmark in close collaboration with centers in Odense, Vejle, Aarhus and
Aalborg, comprising all Departments of Clinical Genetics in Denmark. To be included in the
study, patients must meet at least one of the criteria: RCC < forty years of age or bilateral or
multifocal RCC < sixty years of age or family history of RCC or three relatives with RCC, mel-
anoma or mesothelioma (at least one case of RCC) or patients diagnosed with RCC and mela-
noma. Family history of RCC is defined as two or more first-degree relatives with RCC.
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Patients with a previously identified pathogenic variant in a renal cancer predisposition gene
were not included. Patient inclusion took place from February 2014 to January 2015.
A total of sixty-four families were contacted. Eighteen families did not reply to our requests
or were not interested in being a part of the study. Forty-six families accepted to be included,
but after histopathological examination of the RCCs and examination of the proband’s medical
history, four families were excluded due to having molecular genetically verified VHL (n = 2)
or the renal tumor being a Wilms tumor (n = 2). Six families were included from another
research study or clinical setting at Copenhagen University Hospital (Fig 1).
In six families, the proband was deceased and analyses were performed on cancer-free for-
malin-fixed paraffin-embedded tissue or DNA from banking of a peripheral blood sample
taken at an earlier time.
As shown in Fig 1, the study population consists of three cohorts. Cohort 1 comprises
thirty-two families, who had already been through genetic counselling and hence been
screened for variants in one or more of the RCC predisposition genes VHL, FH, FLCN and
MET without identification of any pathogenic mutations. One patient was identified through a
keyword-based search of the medical record system used at Department of Clinical Genetics,
Copenhagen University Hospital. Cohort 2 comprises nine families, who were included after
identification through the Danish Cancer Registry. The Danish Cancer Registry contains
information regarding all reported cancer incidents in Denmark since 1943. We received data
regarding all patients in Denmark diagnosed with RCC before the age of forty or RCC at any
age in addition to cutaneous or uveal melanoma or mesothelioma. Disease entities were
denoted using ICD7 and ICD10. The oldest entry included in this study dated back to 1979.
Cohort 3 comprises one family identified through the clinical setting at Copenhagen Univer-
sity Hospital and five families, who were identified and included from another study in the
research group. These families have been described in the article ‘Molecular characterization
Fig 1. Flow chart illustrating the inclusion of patients. Cohort 1 comprises families previously genetically counselled.
Cohort 2 comprises patients identified through the Danish Cancer Registry. Cohort 3 comprises one family identified
through the clinical setting at Copenhagen University Hospital and five families identified from another study in the
research group.
https://doi.org/10.1371/journal.pone.0215725.g001
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of melanoma cases in Denmark suspected of genetic predisposition’ by Wadt et al [25]. These
patients only consented to screening for variants in BAP1 and the known E318K-variant in
MITF, which was performed prior to this study. The study population consisted primarily of
participants of European ethnicity and is therefore comparable to the participants of the stud-
ies referred to in this article. S1 Table contains detailed family and clinical information and
data of genetic testing.
Once included all participating families were organized into four groups; in group 1 one
family member was affected with RCC (n = 20), in group 2 two family members were affected
with RCC (n = 21), in group 3 more than two family members were affected with RCC and/or
melanoma (minimum of one RCC) (n = 17) and in group 4 the proband had been diagnosed
with both melanoma and RCC (n = 5) comprising sixty-three family members in forty-eight
families (Table 1 and Fig 2). A questionnaire was filled out regarding all RCC-affected family
members possible to create a baseline description of the participants, and to collect data on
risk factors for RCC and specific tumor details. Data for this baseline description and the expo-
sure to risk factors of RCC was obtained through telephonic interviews with the participants.
If the RCC-affected family member was deceased, the questionnaire was filled out by the
closest living relative on his or her behalf. This was done to the best of their knowledge, and
when relevant data on a given parameter was impossible to obtain, the entity would be filled
out as ‘unknown’. An extraction of the data can be seen in Table 1.
Table 1. Probands and family members diagnosed with RCC.
Group 1 Group 2 Group 3 Group 4 Average Total
Patients/tumors n = 20/25 n = 21/21 n = 17/18 n = 5/5 n = 63/69
Average age at RCC-onset 34.4 56.1 67.7 60.8 56.3
(Range) (25–57) (34–73) (51–89) (43–69) (25–89)
Average age at melanoma-onset - - 49.7 48 49.3
(Range) (25–75) (31–61) (25–75)
Male gender 65% 67% 53% 40% 59%
Smoking status
• Non-smoker 40% 29% 6% 20% 28%
• Smokera 40% 24% 29% 40% 38%
• Unknown 20% 47% 65% 40% 34%
BMI
• Average 28 29 26 30 28
• Median 27 31 25 29 28
• (Range) (20–39) (21–35) (21–34) (29–33) (20–39)
• Unknown n = 3 n = 10 n = 11 n = 2 n = 26
Histology
• Clear cell 13 14 10 1 38
• Papillary 0 1 4 0 5
• Chromophobe 2 0 0 1 3
• Unknown 9 5 4 3 21
• Mixedb 1 1 0 0 2
Group 1 comprises families with 1 case of RCC and an age of onset of 40 (unilateral) - 60 years (bilateral/multifocal). Group 2 comprises families with two cases of RCC.
Group 3 comprises families with three or more cases of RCC and/or melanoma. Group 4 comprises patients diagnosed with both RCC and melanoma.
a’Smoker’ is defined as having smoked 100 cigarettes in a lifetime or having smoked daily for�6 months.
bHistological examination resulted in mixed histology consisting of clear cell + papillary + unknown histology in one tumor in group 1 and clear cell + papillary
histology in one tumor in group 2.
https://doi.org/10.1371/journal.pone.0215725.t001
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The patients were identified, and information obtained using the Danish Civil Registration
System, in which all Danish citizens alive in 1968 or born hereafter, have been registered. All
contacts to the Danish health care system, e.g. medical records, surgical descriptions, histo-
pathological investigations etc. are linked to this registration. We used the Danish Pathology
Data Bank to validate all cases of RCC and melanoma.
Samples and DNA extraction
Thirty-three families included in this study have previously received genetic counseling at one
of the five departments of clinical genetics in Denmark. Genetic counseling includes drawing a
pedigree of at least three generations, validation of reported cancer cases and other relevant
disease entities and collection of blood samples from the proband and/or relevant family mem-
bers for genetic testing. In most families, surplus DNA samples from previous genetic tests
were available for the current study. In the remaining families, the proband and relevant family
members were asked to supply a peripheral blood sample. Basic genetic screening in patients
with potential hereditary renal cancer in Denmark includes the four RCC-genes VHL, FH,
FLCN and MET. The families included from another project in the research group (cohort 3)
only consented to BAP1- and MITF-screening, but the basic screening was performed in all
consenting cohort 1- and 2-families, had it not already been performed at the initial genetic
counselling. Table 2 lists an overview of the genetic tests performed in the study, including the
supplemented basic screening, on patients divided by group and S1 Table lists a detailed over-
view of genetic tests performed on each patient. Previously performed screenings by the clini-
cal genetic departments were not repeated. When possible, we included SDHB, which is
considered part of the basic screening at Copenhagen University Hospital. In this way we
ensured that no pathogenic or likely pathogenic variants were present in any participant, who
consented to basic genetic screening in the VHL-, FH-, FLCN- and MET- genes. In six families,
the patient(s) diagnosed with RCC were deceased. In four of these families we sequenced the
VHL, FH, FLCN, MET, BAP1, MITF and CDKN2B-genes using cancer-free formalin-fixed par-
affin-embedded tissue from the autopsy or a previous operation. In two families, DNA from
previous banking of a blood sample was available, however one unfortunately only held
enough DNA for CDKN2B-analysis.
Sequencing and MLPA analysis
Targeted next-generation sequencing (NGS) was performed from 2014 using a library
designed to capture all exons from the FH, FLCN, MET, SDHB and VHL genes. Sequencing
was performed on a MiSeq (Illumina) to an average depth of at least 100×. Sequencing data
(FASTQ files) were analyzed using Sequence Pilot SeqNext software (v4.0 JSI medical
Fig 2. Schematic presentation of the organization of the participating families into four groups. The organization is based on clinical data. In group 1 one family
member was affected with RCC (n = 20) either RCC< 40 years of age and/or bilateral or multifocal RCC< 60 years of age, in group 2 two family members were affected
with RCC (n = 21), in group 3 more than two family members were affected with RCC and/or melanoma (minimum of one RCC) (n = 17) and in group 4 the proband had
been diagnosed with both melanoma and RCC (n = 5) comprising sixty-three family members in forty-eight families. �No affected first-degree relatives with RCC or
malignant melanoma.
https://doi.org/10.1371/journal.pone.0215725.g002
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systems), where variants were called if the non-reference base frequency was above 25%. The
coding sequences of BAP1 and CDKN2B (and FH, FLCN, MET, SDHB and VHL genes up to
2014) were amplified by PCR using primer pairs flanking each exon followed by sequencing
on an ABI3730 DNA analyzer (Applied Biosystems). MITF was screened for the E318K variant
by TaqMan analysis as recently described [25]. Moreover, genomic DNA was examined for
large genomic rearrangements in the FH, FLCN, SDHB, and VHL genes by multiplex ligation-
dependent probe amplification (MLPA) analysis using SALSA MLPA kits from MRC-Holland.
BAP1, MITF and VHL variants are numbered according to accession number NM_004656.3,
NM_000248.3 and NM_000551.3, respectively, following the guidelines from the Human
Genome Variation Society (http://www.hgvs.org/varnomen). These techniques are not able to
detect large rearrangements.
Variants were classified as ‘pathogenic’ (class 5), ‘likely pathogenic’ (class 4), ‘variants of
unknown significance’ (class 3), ‘likely benign’ (class 2) or ‘benign’ (class 1) following the
IARC classification system [26]. Variants classified as ‘pathogenic’ or ‘likely pathogenic’ are
defined as having a more than 0.99 or 0.95–0.99 probability of actually being pathogenic,
respectively, whereas variants classified as a having ‘unknown significance’ have 0.05–0.949
probability of actually being pathogenic and should not be used for predictive testing. ‘Likely
benign’ and ‘benign’ variants have a low probability of actually being pathogenic (0.001–0.049
and lower than 0.001, respectively) and are treated as ‘no mutation detected’ for RCC.
Ethics
Collection of data regarding the patients’ medical history and initiation of genetic analyses
were performed after written consent had been obtained. We only contacted individuals older
than 18 years of age. Potential participants were contacted by letter with information regarding
the study. If interested in participating, patients were informed about the project by phone and
were sent a letter of consent to sign. When the signed consent form was received, patients
Table 2. Germline variant testing divided by group.
Group 1 Group 2a Group 3 Group 4 Totala
tested/abnormal tested/abnormal tested/abnormal tested/abnormal tested/abnormal
VHL 17/1 14/0 5/0 2/0 38/1
FH 17/0 14/0 5/0 2/0 38/0
FLCN 17/0 14/0 5/0 3/0 39/0
MET 17/0 14/0 5/0 2/0 38/0
SDHB 9/0 7/0 1/0 0/0 17/0
BAP1 20/2 14/1a 8/0b 5/0 47/3
MITF 20/0 15/0a 6/1bc 5/0 46/1
CDKN2B 20/0 14/0a 5/0d 4/0d 43/0
FFPE:Blood 1:19 3:12 0:9 0:5 4:45
Table displaying the germline variant testing in the current study divided by group. For each gene the number in front of the fraction slash in denotes the number of
patients tested. The number behind the fraction slash denotes the number of patients tested with abnormal results. The bottom row indicates the material tested in each
group. Abbreviations: FFPE, formalin-fixed paraffin-embedded tissue.
aIn one family both siblings diagnosed with RCC were screened for the E318K-variant in MITF, only one was screened for variants in BAP1 and CDKN2B.
bIn one family a previously banked blood sample only held enough DNA for CDKN2B-analysis.
cIn two families a previously banked blood sample only held enough DNA for BAP1- and CDKN2B-analyses. The proband in one family had passed away prior to the
present study and the proband in the other family passed away during the study period.
dThe five families included from another project in the research group had only consented to BAP1- and MITF-analyses.
https://doi.org/10.1371/journal.pone.0215725.t002
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were contacted by phone to obtain medical and family history, to fill out a questionnaire
regarding risk factors of renal cancer and to be given the opportunity to ask any questions
there might be regarding the study. Participants have filled out a written consent form to the
use of pedigrees in this article.
The participants were included in a password protected database with name, CPR-number,
data regarding their renal tumor(s) and risk factor questionnaire, and was given a constructed
family number. Only MBC and KW had access to this database. To ensure accuracy, blood
samples were marked with CPR-number, while extracted DNA was anonymized.
The study was approved by the Danish Data Protection Agency and the Committee on
Health Research Ethics in the Capital Region of Denmark (H-1-2013-129).
Results
Variants
Sixteen patients were screened for variants in one or more of the RCC predisposition genes
VHL, FH, FLCN, MET or SDHB (Table 2). No pathogenic variants were found in FH, FLCN,
MET or SDHB, but we did find a start codon variant (c.3G>A, p.Met1Ile) and a missense vari-
ant (c.631A>C, p.Met211Leu) in VHL in a patient from cohort 2 (Fig 3). Both VHL variants are
classified as class 3 variants (VUS) according to the classification guidelines from IARC [26].
In three patients of forty-seven tested, we found variants in BAP1; two missense variants
(c.944A>C, p.Glu315Ala, Fig 4) and (c.1502G>A, p.Ser501Asn, Fig 5) and one intron variant
(c.1729+8T>C, Table 3). The missense variant c.944A>C, p.Glu315Ala is reported in the gno-
mAD database with a frequency of 0.016% in Europeans (non-Finnish). We classify the variant
as a class 3 variant.
The intron variant c.1729+8T>C (rs150945583), which is identified in the patient with two
VHL variants, is reported in the gnomAD database with a frequency of 0.60% in Europeans
(non-Finnish). In silico splicing analysis indicates that the variant has no effect on splicing and
hence it is classified as a class 2 variant. Finally, the novel missense variant c.1502G>A, p.
Ser501Asn is not reported in the gnomAD database and to our knowledge not in the literature,
and is classified as a class 3 variant. Sequencing for the E318K-variant in MITF was performed
Fig 3. Pedigree of family 6002. The arrow indicates the proband. The age of RCC-onset and histological subtype the
renal tumor is listed below the proband (III:3). A start codon VUS (c.3G>A, p.Met1Ile) and a missense variant
(c.631A>C, p. Met211Leu) in VHL and a intron variant (c.1729+8T>C) in BAP1 was identified in a peripheral blood
sample from the proband. The proband’s maternal uncle (II:1) was diagnosed with testicular cancer.
https://doi.org/10.1371/journal.pone.0215725.g003
Exploring the hereditary background of renal cancer in Denmark
PLOS ONE | https://doi.org/10.1371/journal.pone.0215725 April 29, 2019 8 / 16
in forty-five patients with normal results. In one family, we were able to collect DNA from two
relatives with RCC and both were screened for the E318K variant with normal results. In one
family, the patient diagnosed with RCC was found to carry the E318K variant. The patient was
also diagnosed with two non-melanoma skin cancers. Two daughters were diagnosed with
melanoma, one of whom was a carrier of the E318K-variant. The family has been further
described by Wadt et al [25].
The screening of CDKN2B in forty-three patients revealed no variations. An overview of
the genetic tests performed, and variants found, can be seen in Tables 2 and 3 and S1 Table.
Non-genetic risk factors
The average age of RCC-onset in group 1 was 34.4 years, which is more than twenty years
younger than the normal age range of onset of RCC in Denmark (60–69 years). This is most
likely a result of the inclusion criteria and the definition of group 1 and is therefore not
surprising.
Fig 4. Pedigree of family 5001. The arrow indicates the proband. The age of RCC-onset and histological subtype of
the primary renal tumor is listed below the patient (IV:1). A VUS (c.944A>C, p.Glu315Ala) in BAP1 was identified in
a peripheral blood sample from the proband. According to the family’s wishes we did not contact III:3. Additional
cancers in the family are as follows: II:1: Prolactinoma, II:2: Pancreas, II:3: Thyroid, III:2 Sarcoma.
https://doi.org/10.1371/journal.pone.0215725.g004
Fig 5. Pedigree of family 1013. The arrow indicates the proband. The age of RCC-onset and histological subtype of
each primary renal tumor is listed below the patient. A novel VUS (c.1502G>A, p.Ser501Asn) in BAP1 was identified
in a peripheral blood sample from the proband (+) but was not found in two samples of FFPE from the proband’s
brother (-).The proband’s father (I:1) was diagnosed with lung cancer.
https://doi.org/10.1371/journal.pone.0215725.g005
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The age of melanoma onset in group 3 and 4 corresponds to the normal age range of mela-
noma onset in the Danish population. We see a surplus of men, smokers and obese in this
study consistent with the known risk factors for RCC. Two patients could not rule out having
worked with TCE or cadmium, but no certain exposure was documented. No patients had
acquired renal cysts, been through renal dialysis or had a renal transplantation prior to the
onset of RCC.
Histology
As expected, the ccRCC was by far the most common histologic subtype. Of the seven papillary
RCCs, two were found in the same family (II:1 and II:2, Fig 6) in which five family members
had been diagnosed with RCC, one with two primary tumors. The remaining four tumors in
the family were ccRCC (II:3, III:1 x 2 and III:2).
One patient with mixed histology (clear cell + papillary (+ unknown)) had a relative with
ccRCC. The three chromophobe RCCs occur in three different families with RCC-onset of
twenty-five years, thirty-two years and sixty-five years, respectively. We classified 30% of
tumors as unknown histology since it was not possible to find a thorough histopathological
Table 3. Variants found in the present study and clinical characteristics of the families.
ID Age of RCC-
onset
Gene Variant
type
Coding DNA
variant
Protein
variant
Population frequency
(gnomAD NFE)
Clinical
significance
Other cancers in the family
6002,
III:1
28 VHL Start codon c.3G>A p.Met1Ile 0.0016% VUS Testis
VHL Missense c.631A>C p.Met211Leu 0.00079% VUS
BAP1 Intron
variant
c.1729+8T>C 0.60% VUS
5001,
III:1
28 BAP1 Missense c.944A>C p.Glu315Ala 0.016% VUS Sarcoma, prolactinoma, thyroid,
pancreas
1013,
II:2
65 BAP1 Missense c.1502G>A p.Ser501Asn NR VUS Lung
7002 80 MITF Missense c.952G>A p.Glu318Lys 0.25% Pathogenic Basal cell carcinoma, squamous cell
carcinoma, melanoma, breast
https://doi.org/10.1371/journal.pone.0215725.t003
Fig 6. Pedigree of family 2006. The arrow indicates the proband. The age of RCC-onset and histological subtype of
each primary renal tumor is listed below the patient. Additional cancers in the family are as follows: II:1: Lung, II:2:
Rectum, III:2: Prostate, III:3: Unknown.
https://doi.org/10.1371/journal.pone.0215725.g006
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description in the Danish Pathology Data Bank or medical records or because the pathologists
were unable to classify the RCC tumor.
Discussion
We found three VUS’s in BAP1 and two VUS’s in VHL. Forty-six families in the current study,
including thirteen families with melanoma, have been screened for the known E318K-variant
in MITF, but the variant has only been found in one family, which has previously been pub-
lished [25]. No variants were found in CDKN2B. Our cohort was characterized by a surplus of
men, and most patients were overweight and exposed to smoking, all of which are known risk
factors for RCC.
BAP1
The c.1502G>A, p.Ser501Asn variant in BAP1 in family 1013 has not previously been
reported. Pathogenic clues include the highly conserved nucleotide and amino acid involved,
and a SIFT and MutationTaster prediction as ‘deleterious’. However, the variant was not
found in two cancer-free FFPE samples collected from the proband’s brother also diagnosed
with RCC (II:1, Fig 5) and thus did not segregate with RCC in the family. No distant relatives
in the family are known to have been diagnosed with RCC, and therefore it is not possible to
perform further segregation analyses. The variant is classified as a VUS (class 3).
The c.944A>C, p.Glu315Ala variant in BAP1 in family 5001 has not been reported in fami-
lies with BAP1-associated cancers but has a population frequency of 0.016%. Like the above-
mentioned variant, this variant also includes highly conserved amino acids. The physicochem-
ical difference between glutamic acid and alanine is however moderate, and in silico analyses
does not provide a clear answer as to whether the variant is pathogenic or benign. Thus, the
variant is classified as a VUS (class 3).
VHL
The start codon variant (c.3G>A, p.Met1Ile) and missense variant (c.631A>C, p.Met211Leu)
in VHL in family 6002 was found in a patient (III:1, Fig 3), who was diagnosed with ccRCC at
age twenty-eight, but neither he nor any family member have other VHL-manifestations. The
start codon variant substitutes the initial methionine, thus skipping the native start codon with
a yet unknown effect on VHL translation. An alternative start codon at codon 54, which har-
bors the next methionine, is presumed to initiate VHL translation, thus forming an alternative
protein product, which is thought to possess tumor suppressor properties partially similar to
wildtype VHL [27–30]. The p.Met211Leu variant is weakly conserved and there is a small phy-
siochemical difference between methionine and leucine, indicating that the variant is benign.
However due to the lack of functional data, both variants are classified as VUS’s. It is possible
that mosaicism of a third, and pathogenic, variant in VHL could explain the mild VHL-pheno-
type. The patient has been through the national screening program for putative VHL, which
includes MRI of the cerebrum, spinal medulla and abdomen, neurological examination, audi-
tory tests, ocular examination and blood work for chromogranin A and metanephrines, with
normal results. No nationally accepted surveillance program for early renal cancer exits, but
due to his young age at RCC-onset, the patient and his first-degree relatives have been offered
renal ultrasounds every two years.
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MITF
Evidence suggests that the E318K-variant plays a role in the development of melanoma but the
role in the development of RCC is unclear. Recent studies do not find an association between
the E318K-variant and the development of RCC, neither does the current study [31,32]. A pos-
sible association between the E318K-variant and the development of pheochromocytoma and
paraganglioma has been proposed recently by Castro-Vega et al, illustrating that the cancer
spectrum of the E318K-variant, if any, is not yet fully elucidated [33]. Further studies should
be performed in renal cancer families to elucidate the impact of the E318K-variant in the
development of RCC.
CDKN2B
We found no variants in CDKN2B and are therefore not able to confirm the findings of Jafri
et al regarding CDKN2B as a RCC predisposing gene [24].
Two different putative RCC-genes include PTEN known for its involvement in Cowden
syndrome, in which patients have a genetic predisposition to RCC, and PBRM1 in which a het-
erozygote germline variant was found to segregate with RCC in four affected family members
in a French RCC-family [34]. The proband of one family in the current study was screened for
variants in PTEN prior to inclusion, but in the remaining families PTEN screening was not
considered relevant by the Departments of Clinical Genetics initially performing the genetic
counselling. The families in cohort 2 and 3 did not have pedigrees suggestive of Cowden
syndrome.
We have not investigated the involvement of PBRM1 in RCC-tumorigenesis. Our cohort
consisted of forty-eight families suspected of having a genetic predisposition to RCC, but
where the most common RCC-associated syndromes had been excluded. The average age of
RCC-onset in this study is 56.3 years (Table 1), which is younger than the average onset of
RCC in the Danish population (64.4 years in 2013). Excluding group one, which is heavily
biased in this aspect, the average age of RCC-onset in this study is 61.3 years, only 3.1 years
younger than the average onset in the general population. Early onset of RCC could indicate
genetic susceptibility to cancer, but in regard to other life style factors known to be risk factors
of RCC, the patients in this study have a high consumption of tobacco and are generally obese.
In 2017 the National Board of Health published ‘Danskernes Sundhed—Den Nationale Sund-
hedsprofil’, a report created using data from questionnaires filled out by more than 170,000
Danish citizens [35], 16.9% of responders report that they smoke daily. The highest percentage
of the population smoking daily is in the age group 55–64 years, in which 21.9% of men and
20.3% of women report daily smoking. In the age group 16–44 years, 17.1%-18.4% (men) and
13.5–15.3% (women) of the population report daily smoking. In the current study a large per-
centage of the patients in each group, 40% of the patients in group 1 and 4, are reported as
smokers, which is massive, compared to the general population, albeit the sample size is small.
The average BMI is>25 in all groups and in group 4 all participants are overweight. In the
general population 57.7% of men and 44.4% has a BMI of>25. Only four patients in this study
have a BMI <25 and are non-smokers. The average age on RCC-onset in these patients is 47.6
years (28–66 years). We see a surplus of men in the study except for group 4, where the surplus
of women might reflect that more women than men expose themselves to high amounts of
UV-radiation leading to development of melanoma.
Since habits such as smoking, sedentary lifestyle and unhealthy diet tends to accumulate in
families as well as genetic predisposition, distinction of the influence of hereditary and envi-
ronmental factors on RCC is difficult. The most likely explanation to the RCC diagnoses in the
current study is that many cases of RCC are multifactorial; arising from a combination of
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moderate genetic risk factors for RCC and non-genetic risk factors and exposure to environ-
mental factors might play a non-negligible role in the development of renal cancer in some of
the individuals of the current study.
Of the tumors in this study 79% were described as clear cell, 10% were papillary and 6%
chromophobe consistent with the distribution found in the literature. It was not possible to
classify 30% of tumors. Histopathological sub classifications of RCCs are done by evaluating
the morphology of the tumor specimen. Until 2016, the ‘2004 WHO Classification of the
Renal Tumors of the Adults’ has been used as a reference for the morphological description.
Here ten different histological subtypes of RCCs are described (clear cell, multilocular cystic,
papillary, chromophobe, collecting duct carcinoma, medullary carcinoma, RCC associated
with Xp11.2 translocations, RCC associated with neuroblastoma, mucinous, tubular and spin-
dle cell carcinomas and the unclassified carcinomas) [36]. Immunohistochemistry is recom-
mended to elucidate or support the classification if the morphology is unclear. In their article
from 2011 Algaba et al describes further sub classifications of RCC including the subtype clear
cell papillary RCC, with morphological changes from both subtypes in one tumor [37] and in
the new ’2016 WHO Classification of the Renal Tumors of the Adults’ the ‘clear cell papillary
renal cell carcinoma’ has been denoted as a separate entity [38]. It is possible, that the two
mixed tumors included in this study, should in fact be reclassified as belonging to this sub-
group. Clinical relevance of the new classification is not yet evident. Two BAP1-variant carriers
(6002, III:1 and 1013, II:2 (Table 3)) was diagnosed with ccRCC and one MITF-variant carrier
(7002, (Table 3)) was diagnosed with papillary RCC. Few E318K-carriers have been diagnosed
with RCC, but the most prevalent histological subtype described in the literature is clear cell
carcinoma [21]. One of the strengths of this study is its national approach comprising families
previously genetically counselled due to suspected hereditary RCC syndrome. Seventy-two
percent of the invited patients accepted to be included in the study. However, some families
with several cases of RCC might not have been identified prior to this study and therefore have
not been offered genetic counselling. Some have not been interested. To minimize this selec-
tion bias, we have applied data from the Danish Cancer Registry about all Danish citizens with
an onset of RCC before the age of forty since 1979. These patients were denoted cohort 2,
which also includes the patients with RCC and melanoma found through the Danish Cancer
Registry. Throughout the study, we have identified and monitored patients through the Danish
Civil Registration System and validated RCCs and other tumors of interest using the Danish
Pathology Data Bank, giving the data in the study high validity.
Conclusion
We screened forty-nine family members in forty-eight families for variants in one or more of
the RCC causative genes VHL (n = 10), FH (n = 11), FLCN (n = 10), MET (n = 11) and SDHB
(n = 9) and the putative RCC-genes BAP1 (n = 47), MITF (n = 46) and CDKN2B (n = 43). We
found two VUS’s in VHL in a patient with onset of RCC at twenty-eight years of age and no
family history of RCC or other VHL-manifestations. Furthermore, we found three VUS’s in
BAP1, of which one was novel and non-segregating in the family, and the E318K variant in
MITF in one patient of a family with melanoma and RCC. Since the BAP1 variants are classi-
fied as VUS’s, a standardized surveillance program for variant carriers is not relevant. A sur-
veillance program has not been established for E318K variant carriers, but increased awareness
of potentially malignant cutaneous lesions and symptoms of renal disease should be advised.
In a clinical setting, we now routinely perform genetic testing of VHL, MET, FH, FLCN, MITF,
BAP1, PTEN, SDHB, and CDKN2B in individuals and families suspected for genetic predispo-
sition to RCC. The results of the study indicate that germline variants in BAP1, MITF and
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CDKN2B are not frequent in Danish families with suspected hereditary predisposition to renal
cancer, and in the families of this study a possible genetic background of RCC is still unre-
solved. Furthermore, the results indicate that non-genetic risk factors of renal cancer play a
key role in renal cancer pathogenesis in families suspected of hereditary predisposition to
renal cancer where the most common RCC syndromes have been excluded. Further genetic,
epigenetic and epidemiological investigations into putative predisposing genes and risk factors
of RCC are necessary to fully elucidate RCC-pathogenesis and predict risk of renal cancer in
families with hereditary predisposition to renal cancer.
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